WellPrept Patient Education · Cancer Series

Understanding Localized Prostate Cancer

A guide for men whose prostate cancer is still inside the prostate. You will have several reasonable options to choose from, and this walks through each one so you can decide with your team.

Version 1.0 · May 2026 Medically reviewed · Next review May 2027

Welcome

Hearing the words "you have prostate cancer" hits hard, and the first urge for most men is some version of "just get it out." For some men that is the right call. For many men with localized prostate cancer, jumping straight to surgery trades a slow-growing cancer for side effects on leakage and sex that they could have skipped, or at least delayed by years.

Localized prostate cancer rarely needs a decision in days. A few weeks to read, ask questions, and get a second opinion will not change your outcome. Most localized prostate cancers grow slowly, some grow faster, and the workup your team runs over the next few weeks is built to tell those two situations apart before you commit to a plan.

This guide pairs with the Cancer Basics guide, which covers words like grade, stage, and active surveillance in plain terms. Read that one first if you have not yet.

How to use this guide. Read it at your own pace. Your risk group is in Chapter 4, and the treatment options in Chapters 5 and 6 are built around that group. Chapter 13 has questions you can bring to your next visit.

Chapter 01

What localized prostate cancer is

Localized means the cancer is still inside the prostate. It has not reached lymph nodes or other organs. Most men diagnosed today are in this group.

The situation

A biopsy has shown prostate cancer. Imaging and your exam suggest the cancer is still inside the prostate. Doctors call this clinically localized disease. It is the most common way prostate cancer is found in the US.

About 1 in 8 men in the US will be diagnosed with prostate cancer at some point. That is about 300,000 new cases each year. Most are found at the localized stage through PSA testing. Most men in your group will not die of their prostate cancer.

1 in 8
Lifetime risk of prostate cancer for men in the US. Most cases are found at the localized stage.
~300,000
New US cases each year. Most show up through PSA testing, not symptoms.
Most
Men in this group will not die of their prostate cancer. The workup finds the men who do need treatment.

A few weeks will not change your outcome

Most men want to act in the next few days. By the time a localized prostate cancer shows up on PSA testing, it has usually been growing for years, so an extra three or four weeks to read, ask questions, and get a second opinion will not change your cancer outcome. It can change which treatment you pick, and that matters more.

What you are choosing between

You will hear about several options. Watching the cancer closely with regular tests. Surgery to remove the prostate. Different forms of radiation. A treatment of only the part of the prostate that has cancer. For some men in higher-risk groups, hormone therapy added to radiation. None of these is the only right answer for every man. The right choice depends on your risk group, your other health, and what matters to you.

!
Slow growing for most, not all

Many localized prostate cancers, left alone, would never cause symptoms or shorten a man's life. Others would. The workup over the next few weeks is built to sort your cancer into one of those two groups. It uses the Gleason score, an MRI, and sometimes a tumor classifier test, all before you commit to treatment.

Chapter 02

How it gets found and diagnosed

Most localized prostate cancers come to light through a blood test, not symptoms. A few tests later, you have a diagnosis and a starting picture.

The PSA blood test

PSA stands for prostate-specific antigen. It is a protein made by prostate cells, normal and cancerous. PSA can go up with prostate cancer. It can also go up with an enlarged prostate, a prostate infection, recent sex, and age. PSA does not diagnose cancer on its own. It flags men who need a closer look.

The rectal exam

Your doctor feels the back wall of the prostate through the rectum with a gloved finger. A hard spot or a bump can suggest cancer. The exam is brief and not painful for most men.

The prostate MRI

A special scan of the prostate is now common after an elevated PSA. The radiologist reports a score from 1 to 5. A 1 or 2 is unlikely to be cancer. A 3 is in between. A 4 or 5 is likely cancer and will be targeted at biopsy. Some men with low PSA density and a low MRI score may be able to skip a biopsy for now.

The biopsy

A biopsy is the test that makes the diagnosis. A doctor takes about 12 small tissue cores from the prostate under ultrasound guidance, plus extra cores aimed at any spot the MRI flagged. There are two routes. One goes through the rectum. The other goes through the skin between the scrotum and the anus. The second route has lower infection risk and is offered more and more.

Staging scans, when needed

Many low-risk and favorable-risk cancers need no scans past the prostate MRI. Higher-risk cancers call for more. The two main scans are a bone scan and a newer scan called prostate-specific membrane antigen (PSMA) PET. PSMA PET targets a protein on prostate cancer cells. It is now the go-to staging scan at most US cancer centers for unfavorable intermediate-risk disease and above.

i
Ask for a copy of your pathology report

You are allowed to have it. Bring it to your next visit. Mark words you do not know. Your team will walk through it with you. The numbers and words on that report decide which treatment options are open to you.

Chapter 03

Reading your pathology report

Three numbers do most of the work on your report. Once you know what they mean, the rest of the report makes more sense.

WatchYour biopsy report, line by lineA short video, on YouTube (youtu.be/xq0axtfSs6I)

Gleason score

A pathologist looks at the cancer under a microscope and gives a pattern from 1 (most normal) to 5 (most abnormal). The most common pattern and the second most common pattern get added together. The lowest score that gets called cancer is a Gleason 6 (which is 3 plus 3). Higher means more aggressive.

  • Gleason 6 (3+3): the least aggressive cancer that is still called cancer
  • Gleason 7 (3+4): mostly less aggressive pattern, some more
  • Gleason 7 (4+3): mostly more aggressive pattern
  • Gleason 8 (4+4); Gleason 9 (4+5 or 5+4); Gleason 10 (5+5)

Grade Group

A simpler 1 to 5 scale reported alongside Gleason. Grade Group 1 is Gleason 6. Grade Group 2 is Gleason 3+4. Grade Group 3 is Gleason 4+3. Grade Group 4 is Gleason 8. Grade Group 5 is Gleason 9 or 10. Many teams use Grade Group as the easier way to talk through this.

Why 3+4 and 4+3 are different

Both are Gleason 7. The order matters. In 3+4, most of the cancer is the less aggressive pattern. In 4+3, most is the more aggressive pattern. The difference moves men between the favorable and unfavorable intermediate-risk groups in Chapter 4.

Other words on the report

  • Number of cores positive. How many of the biopsy samples had cancer.
  • Percent of each core involved. How much of the sample was cancer.
  • Perineural invasion. Cancer along a small nerve in the prostate. It is a risk feature, not a sign of spread.
  • Cribriform pattern and intraductal carcinoma. Aggressive patterns under the microscope. If you see these words, ask your team how they shape your plan. They sometimes move men out of the favorable intermediate group.
!
There is no Gleason 1 to 5 anymore

Modern pathology does not assign Gleason scores under 6. If your report says cancer, the lowest possible score is Gleason 6 (Grade Group 1). A Gleason 6 is still cancer, and it is the least aggressive form. Many men with Gleason 6 are watched safely on active surveillance.

Chapter 04

Your risk group sets your options

In localized prostate cancer, your risk group matters more than your stage. The treatment options are built around it.

Where the risk group comes from

The risk group comes from a system called NCCN. It uses your PSA, your Grade Group, how the cancer feels on exam, and details from your biopsy. The system sorts men into six bands. Your team can tell you yours.

The six bands

Very low
Watch first
Small amount of Grade Group 1 cancer, PSA under 10. Active surveillance for nearly all men.
Low
Watch first
Grade Group 1, PSA under 10. Active surveillance preferred for most men.
Favorable intermediate
Watch or treat
Grade Group 2 (3+4), or one other intermediate feature. Active surveillance for selected men. Surgery or radiation also reasonable.
Unfavorable intermediate
Treat
Grade Group 3 (4+3), or two or more intermediate features. Surgery or radiation, often with short-term hormone therapy added to radiation.
High
Treat
Grade Group 4 or 5, or PSA over 20. Surgery with node removal, or radiation with longer hormone therapy.
Very high
Treat
Several high-risk features at once. Radiation plus longer hormone therapy, with newer drugs sometimes added. Surgery in selected cases.

Why this matters for your options

Active surveillance is an option for very low, low, and select favorable intermediate-risk men. Surgery and radiation are options across the intermediate and high-risk groups. Hormone therapy comes in for higher-risk cancers, mostly alongside radiation. Chapters 5 and 6 walk through each.

i
Ask for your risk group, in those words

Ask at the first visit: "What is my NCCN risk group, and how does that change what you are recommending?" The answer points you to the right chapter and the options that apply to you.

Chapter 05

Active surveillance, in plain terms

Active surveillance watches the cancer with regular PSA tests, plus an MRI and biopsy from time to time. It sets a clear trigger to switch to surgery or radiation if the cancer changes.

Why it exists

A large share of low-risk prostate cancers grow slowly enough that they would never cause symptoms in a man's lifetime. Surgery or radiation for those cancers can still leave permanent changes to leakage and sex, which is why guidelines have moved toward watching first for low-risk and select favorable intermediate-risk men instead of treating up front.

What active surveillance looks like in practice

  • A PSA blood test about every 6 months
  • A rectal exam about once a year
  • A prostate MRI about every 12 to 18 months
  • A repeat biopsy within the first 6 to 12 months to confirm the picture
  • A surveillance biopsy every 1 to 3 years after that, based on the trend
  • Sometimes a tumor gene test on the biopsy tissue to sharpen the plan

When the plan switches to treatment

Your team will move you to treatment for a few clear reasons. Your repeat biopsy shows a higher Gleason pattern. The amount of cancer has clearly grown. A new spot shows up on MRI. Or your PSA rises in a way that has no other explanation. You can also choose to switch at any point if watching no longer feels right.

How often men move to treatment

About 30 to 50 out of 100 men on active surveillance for low-risk cancer move to treatment over 10 to 15 years. Most of those men can still be cured when they do. Active surveillance is the preferred starting plan for low-risk disease in current US and European guidelines. It is offered more and more for Grade Group 2 cancers with no other adverse features.

+
If your urge is "just take it out"

Most men feel that pull in the first week after a diagnosis. Before you act on it, ask your team three specific things. Ask what surveillance schedule they would use, and the exact trigger that would move you to treatment. Ask for the 15-year data on men in your risk group.

Chapter 06

Surgery, radiation, and focal treatment

When the plan is to treat, you have three kinds of options: surgery, radiation, and focal treatment. Each one has its own cancer-control numbers. Each also has its own side effects for urinary control, sex, and bowel function.

Surgery: radical prostatectomy

The whole prostate and the seminal vesicles come out, and the cancer comes out with them. Most US surgeries today are done with a robot through small cuts. An open approach is less common but works well in skilled hands. Many urologists offer both. Surgeon experience matters more than the specific approach. High-volume surgeons have lower rates of cancer at the edge of the specimen, no matter the route.

The nerves that drive erections run alongside the prostate. When it is safe for the cancer, your surgeon will spare one or both nerve bundles. Nerve-sparing, when it is appropriate, is the strongest predictor of erectile recovery. For higher-risk cancers, the surgeon may also remove the lymph nodes in the pelvis at the same time.

External beam radiation

High-energy beams from outside the body are aimed at the prostate, with or without nearby lymph nodes. Modern treatment is precise. The most common plan today is 20 sessions over 4 to 5 weeks. A shorter course of 5 sessions over 1 to 2 weeks, called SBRT, is now an option for low and intermediate-risk disease with similar results in studies. A proton beam option exists at some centers. Results are similar; cost is higher.

Brachytherapy: radiation from inside

Radioactive sources are placed inside the prostate. The most common form uses permanent seeds. The seeds give off radiation over a few months and then stay in place. Brachytherapy works best for low and favorable intermediate-risk disease as a single treatment. For higher-risk disease, it can be added to external beam radiation as a boost.

Focal therapy

Focal therapy treats only the part of the prostate that has cancer and leaves the rest in place. The goal is to control the main tumor and spare more leakage and sex function than full-gland treatment. Several methods are in use, including focused ultrasound and freezing. It fits a smaller group of men: someone with one main cancer spot in the favorable or unfavorable intermediate-risk range who accepts ongoing checks on the rest of the prostate. For low-risk disease, active surveillance is the first choice rather than focal therapy. Focal therapy is also not the first choice for high-risk disease, where the cancer is usually too spread out inside the prostate. Long-term data past 10 years is still thin, and insurance coverage varies.

Hormone therapy added to radiation

Testosterone fuels prostate cancer. Lowering it slows growth. Hormone therapy is called androgen deprivation therapy (ADT). On its own it does not cure localized disease. Doctors add it to radiation in higher-risk cancers. The plan runs 4 to 6 months for unfavorable intermediate-risk. It runs 18 to 36 months for high and very high-risk. Hormone therapy is most often left out in favorable intermediate-risk.

Chapter 07

Side effects, side by side

Every active treatment for localized prostate cancer trades cancer control for some cost on leakage, sex, or bowel. The table below shows the numbers side by side. In the erection column, the surgery rows give the share of men who keep erections. The radiation rows give the share who develop new problems.

OptionLeakage at 12 monthsErectionsEjaculation & orgasmBowel
Active surveillanceUnchangedUnchangedUnchangedUnchanged
Surgery (nerve-sparing, healthier man)About 80 to 90 out of 100 men dry or one safety padAt 12 to 24 months, about 50 to 70 out of 100 men have erections firm enough for sex, often with a pillNo fluid (dry orgasm). Climacturia (urine leak at orgasm) in the first year for some men. Altered orgasm intensity for someUnchanged
Surgery (higher-risk, wider operation)About 75 to 85 out of 100 men dry or one padAt 12 months, about 15 to 30 out of 100 men have erections firm enough for sexNo fluid. Climacturia and altered orgasm more commonUnchanged
External beam radiationMost men keep good control. Some new urinary symptomsNew erection problems in about 30 to 50 out of 100 men by 5 yearsEjaculate volume drops over time. Many men have none by 5 years. Altered orgasm reported by someNew chronic bowel changes in about 5 to 15 out of 100 men. A spacer gel lowers this
Brachytherapy (seeds)Most men keep good control. Urinary frequency and weak stream are common in the first yearNew erection problems in about 30 to 50 out of 100 men over 3 to 5 yearsLess fluid. Altered orgasm for someLess than external beam
Hormone therapy with radiationNo direct effect on leakageStrong negative effect while on hormone therapy. Slow recovery afterNone while on hormone therapyNo direct effect
Focal therapyMost men keep good controlBetter preserved than full-gland treatmentOften present, with less fluidRare

Sexual side effects in detail

Sexual function is the side effect most men ask about. Be direct with your team. Ask for your own expected numbers based on your age, your starting function, and your cancer. The numbers above are wide ranges from large studies. Your urologist can narrow them for you.

  • Climacturia. Urine leakage at orgasm. Common in the first year after prostate surgery for some men. It usually improves. Pelvic floor exercises and a tension loop help.
  • Penile shortening. A loss of about 1 to 2 cm is reported in a substantial fraction of men after surgery. It is less common after radiation. Early use of erection medications and a vacuum device may help limit it.
  • Altered orgasm. Orgasm can feel different after either treatment. Some men report lower intensity. A few men report no orgasm at all. Some men have pain with orgasm in the first months.
+
Surgery vs radiation

Surgery has more leakage and a bigger early hit to erections. Radiation has more late effects and slower-onset erection problems. Hormone therapy affects many parts of the body while you are on it, and most of those effects fade after it ends. Active surveillance has none of these costs unless or until you switch.

Chapter 08

Living with the choice

The first weeks

The first few weeks after a diagnosis tend to crowd out everything else, and most men feel pushed to act fast. With localized prostate cancer, a few weeks of reading and second opinions will not change your cancer outcome. They will often change your plan in ways that matter for the next 20 years.

Scanxiety and PSA anxiety

The week before a PSA or scan on active surveillance is hard for many men. Scanxiety is the usual name for it. A few practical things make it more tolerable. Scheduling the test for early in the week shortens the wait. Booking a short follow-up call within 48 hours of the result keeps a hard number from sitting unread for days. Sometimes the worry gets in the way of sleep, work, or your relationships. If it does, two or three sessions with a therapist who works with cancer patients often helps.

Sex and partners

Sex will change after any active treatment. After surgery, ejaculation goes away from day one, and erections take 6 to 24 months to recover, often with help from a daily pill, a vacuum device, or injections. Some men also have urine leakage with orgasm in the first year. After radiation, the changes come on more slowly, usually over 2 to 5 years. If you have a partner, the conversation goes easier before treatment than after. Bringing them to one of your visits, even just to hear the numbers in Chapter 7, is a reasonable move.

Continence and the pelvic floor

Pelvic floor exercises (Kegels) help leakage after surgery. Many teams ask men to start these before surgery, not after. Most men reach good urinary control within 6 to 12 months. A smaller group needs more help, including a small device placed in a second operation.

Money and work

Different treatments have very different costs and time commitments. Surgery is one operation with weeks of recovery. Radiation is 4 to 9 weeks of short daily visits. Active surveillance is a long chain of visits over many years. Ask your team's social worker or financial counselor early. Most cancer centers have one.

Fertility, if it applies

Most men with localized prostate cancer are past the age where this comes up. For men who do want children, surgery and radiation both end the ability to father a child naturally. Sperm banking before treatment is the answer. The window is narrow.

Chapter 09

What the ProtecT study showed

The most important study in localized prostate cancer is called ProtecT. Over 1,600 men in the UK were assigned to active monitoring, surgery, or radiation. They were followed for 15 years. The findings shape how men in your group choose today.

The headline at 15 years

  • Deaths from prostate cancer were low in all three groups, and similar. About 3 out of 100 in the monitoring group. About 2 out of 100 in the surgery group. About 3 out of 100 in the radiation group.
  • Spread of cancer was higher in the monitoring group but still small. About 9 out of 100 monitored. About 5 out of 100 in each treatment group.
  • Total deaths were similar. Most men in all three groups died of other things, not prostate cancer.
  • Quality of life was worst for surgery on leakage and sex. Radiation had a smaller effect on bowel and sex. Monitoring spared men those costs unless they later moved to treatment.
For most men with PSA-found localized prostate cancer in a lower-risk group, the choice between watching, surgery, and radiation comes down to which side effects you would rather take on, since 15-year survival is similar across all three.

What ProtecT does not answer

The men in ProtecT were mostly low and intermediate-risk. So the results say less about men in the high or very high-risk groups. For those men, treatment does lower the chance of spread and of dying from prostate cancer. Today's active surveillance plans also do more testing than the monitoring arm in ProtecT. That likely catches changes sooner.

What to take from it

If you are in a lower-risk group, survival at 15 years is similar across all three paths. So the decision is mostly about which set of costs and benefits fits the life you want. If you are in a higher-risk group, active treatment does lower the chance of spread and of dying from prostate cancer. There the talk with your team should weigh cancer control more heavily. Either way, ask your team to set your own age, your other health, and your risk group against these ProtecT numbers before you decide.

Chapter 10

Family, genes, and what to test

Most prostate cancer is not inherited. A meaningful share is tied to inherited genes that also matter for your brothers, your sons, and your daughters. Two kinds of tests come into play.

Germline testing: testing you

A blood or saliva test looks for gene changes you were born with. Your team may suggest the test for any of these reasons. A strong family history of prostate, breast, ovary, pancreas, or colon cancer. Ashkenazi Jewish ancestry. A Grade Group 4 or 5 cancer. Cribriform or intraductal patterns on your biopsy. Your own past history of another cancer.

The test looks at several genes. BRCA1 and BRCA2 are the best known. They raise the risk of more aggressive prostate cancer. They also matter for breast, ovary, and pancreas cancer in your relatives. Other genes on the panel include ATM, CHEK2, and PALB2. The Lynch syndrome genes are also checked. They raise the risk of prostate, colon, and other cancers. A positive result affects more than your own care.

Why it matters for your family

An inherited mutation in you means each of your brothers, sisters, sons, and daughters has a 1 in 2 chance of carrying the same gene change. Relatives can be tested through a process called cascade testing. A genetic counselor walks them through it one at a time. The hardest part for most men is telling adult children, since there is often no obvious right moment. Your genetic counselor can write a short letter for you to forward. It explains the medical side for you and gives your family something to bring to their own doctor.

A note on insurance

A federal law called GINA blocks health insurance and employers from using your genetic test results against you. It does not cover life, disability, or long-term care insurance. A genetic counselor can walk you through this before you test.

Tumor classifier tests

A separate set of tests can be done on your biopsy or surgery tissue. The most common name is Decipher. These tests give a score that says how aggressive the cancer is likely to be. The score does not replace your Gleason or Grade Group. It adds a second layer that can help a borderline plan settle one way or the other. Your team may use it to decide if a Grade Group 1 cancer is safe to watch, or whether a Grade Group 2 cancer needs more than radiation alone.

i
Tell your kids on your timeline

You do not have to share results the same day you get them. But if a gene change comes back, your siblings and children deserve the chance to know. Many men find it helps to ask a genetic counselor for a short letter they can forward to family. The counselor can be the messenger when that helps.

Chapter 11

What you can do on your own

The habits below do not replace the treatment plan from your team. They help your body handle treatment and help you feel better during recovery.

Before you decide

  • Slow down. Localized prostate cancer rarely calls for a decision in days. A few weeks to read and ask questions is reasonable.
  • Get a second opinion. A urologist and a radiation doctor looking at the same case can point out options one alone might miss. This helps most for high-risk disease.
  • Ask if your case has been at tumor board. A tumor board is a group of cancer doctors reviewing cases together. Asking is normal.
  • Bring a list of questions, and bring someone with you. Two sets of ears in the room helps.

Before treatment

  • Get baseline numbers. Many teams use short forms to track sexual function and leakage before treatment. Those baseline numbers help you see what changes after.
  • Start pelvic floor exercises. Kegels are squeezes of the muscles you would use to stop urine. Starting them before surgery helps with leakage after.
  • Stop smoking. Smoking slows healing after surgery. It also makes long-term radiation side effects worse.
  • Move your body. Watch your weight. A strong heart and good fitness help recovery. They may also help slow prostate cancer over time.
  • Ask about clinical trials at diagnosis. Trials sign up men in many risk groups, including men with localized disease.

If you choose active surveillance

  • Show up for every scheduled PSA, MRI, and biopsy. The plan only works if the tests get done.
  • Keep a simple log of your PSA values over time. Trends matter more than any one number.
  • If you notice any new urinary changes between visits, tell your team.
+
The plan is yours

Some men want the highest chance of erasing the cancer, even at a cost to leakage or sex. Other men will accept a slightly higher recurrence risk to keep daily function as close to baseline as possible. The right recommendation from your team should reflect what you tell them about that tradeoff, alongside the numbers in your risk group.

Chapter 12

When to call, and follow-up

Most days, the right move is to keep your scheduled visit and bring questions. A few situations call for a faster response.

!
Same-day or ER

Unable to pass urine at all. Heavy blood from the urine or rectum. Fever with chills, especially after a biopsy. Sudden swelling in one leg, chest pain, or trouble breathing (these can be signs of a blood clot, a risk after surgery and on hormone therapy). Severe pain you cannot manage at home.

Call your team this week

  • New leakage, worse leakage, or a new need to rush to the toilet between visits
  • Bowel problems that last more than 3 months after radiation
  • Trouble with erections, where starting help sooner tends to work better than waiting
  • Hot flashes, mood changes, or feeling tired while on hormone therapy
  • Any feeling that the plan no longer makes sense to you

Follow-up after treatment

The exact schedule varies. A common pattern after surgery or radiation is a PSA every 3 to 6 months for the first 1 to 2 years, then every 6 months, then once a year. The rectal exam is done now and then. Scans are added only if the PSA rises or symptoms develop.

After surgery, your PSA should drop to undetectable. A rise to 0.2 ng/mL or higher on two checks is called biochemical recurrence. After radiation, your PSA reaches a low point over 1 to 2 years. A rise of 2.0 ng/mL above that low point is called biochemical recurrence. Both definitions trigger more workup and a discussion about next steps.

Survivorship

Follow-up visits cover more than just the cancer. Your team also checks on leakage and sexual function. If you are on hormone therapy, they will also check your bone health, heart health, and lab numbers. Radiation carries a small extra risk of bladder or rectal cancer over many years. These topics get more time as the cancer side of the visit slows down.

Chapter 13

Questions to ask your team

Bring this page to your next visit so you have the questions in front of you.

About my cancer

  • What is my Gleason score and Grade Group?
  • What is my NCCN risk group?
  • Does my biopsy show a cribriform or intraductal pattern?
  • Has my case been reviewed at a tumor board?

About my options

  • Is active surveillance a fair option for me?
  • If we move to treatment, what are the options for me, and which are you leaning toward?
  • Would a tumor classifier test like Decipher change anything for my case?
  • If surgery, will you spare the nerves? On one side or both?
  • If radiation, which type, how many sessions, and would a rectal spacer help me?

About side effects

  • What is the expected chance I will be dry at one year?
  • What is the expected chance I will have erections firm enough for sex at one year, with and without a pill?
  • What are the bowel side effects to expect with radiation?
  • What does penile shortening look like in your hands?
  • Is hormone therapy part of the plan? For how long? What side effects should I plan for?

About family

  • Should I see a genetic counselor?
  • Should I tell my siblings or my children to get tested?
  • What about my children's PSA screening?

About the path ahead

  • What is the schedule of visits and tests after treatment?
  • How will we know if the cancer comes back?
  • What is your honest sense of what is realistic for me?
Chapter 14

Words to know

General cancer words live in the Cancer Basics guide. These are the ones used most in localized prostate cancer care.

PSA
Prostate-specific antigen. A blood test that goes up with prostate cancer, an enlarged prostate, infection, and age.
PSA density
The PSA value divided by the prostate volume. Helps make sense of a borderline PSA.
Digital rectal exam (DRE)
A gloved-finger exam to feel the back wall of the prostate.
Prostate MRI
A scan of the prostate, scored 1 to 5. A 4 or 5 is likely cancer and gets targeted at biopsy.
Biopsy
Small tissue samples from the prostate, looked at under a microscope.
Transperineal biopsy
A biopsy route through the skin between the scrotum and the anus. Lower infection risk than the route through the rectum.
Gleason score
A pathology grade. The sum of the two most common cancer patterns. Range 6 to 10.
Grade Group
A simpler 1 to 5 scale that maps onto Gleason.
Cribriform pattern
An aggressive microscope pattern that can shift treatment.
Intraductal carcinoma
Another aggressive pattern often grouped with cribriform.
Perineural invasion
Cancer along a small nerve in the prostate. A risk feature, not spread.
NCCN risk group
A six-band system that sorts localized prostate cancer into very low through very high risk.
PSMA PET scan
A scan that targets a protein on prostate cancer cells. Used for higher-risk staging.
Active surveillance
A treatment plan of regular PSA, MRI, and biopsy, with a clear trigger to switch to active treatment if the cancer changes.
Radical prostatectomy
Surgical removal of the prostate and seminal vesicles.
Nerve-sparing
A surgical step that preserves the erectile nerves alongside the prostate when it is safe for the cancer.
Pelvic lymph node dissection
Removal of the pelvic lymph nodes at the same operation, for staging in higher-risk cancers.
EBRT
External beam radiation. High-energy beams aimed at the prostate from outside the body.
SBRT
A short course of high-dose EBRT given in only 5 sessions.
Brachytherapy
Radiation from sources placed inside the prostate. Seeds are most common.
Rectal spacer
A gel placed between the prostate and rectum before radiation to lower bowel side effects.
Focal therapy
Treatment of only the part of the prostate that has cancer. Several methods.
ADT
Androgen deprivation therapy. Hormone treatment that lowers testosterone to slow prostate cancer.
Decipher
A tumor classifier test that scores how aggressive a prostate cancer is likely to behave.
BRCA1, BRCA2
Inherited genes that raise risk of aggressive prostate cancer and matter for relatives.
Lynch syndrome
An inherited condition that raises risk of prostate, colon, and other cancers.
Climacturia
Leakage of urine at orgasm. Common in the first year after prostate surgery.
Biochemical recurrence
A rising PSA after treatment. Defined differently for surgery and radiation.
Tumor board
A group of cancer doctors who review cases together to agree on a plan.
ProtecT
The large UK study that compared monitoring, surgery, and radiation in localized prostate cancer. 15-year results published in 2023.
Sources

Sources and further reading

This guide draws on current society guidelines and the major trials behind today's standard of care. The list below points to where you can read more.

  1. NCCN Prostate Cancer Guidelines. nccn.org
  2. NCCN Patient Guidelines: Prostate Cancer. nccn.org/patients
  3. EAU Prostate Cancer Guidelines 2025. uroweb.org
  4. ProtecT 15-year results (Hamdy et al., NEJM 2023). nejm.org
  5. ProtecT 10-year results (Hamdy et al., NEJM 2016). nejm.org
  6. PACE-B trial (SBRT vs conventional EBRT). pubmed.gov
  7. ASCENDE-RT (brachytherapy boost). pubmed.gov
  8. STAMPEDE platform trial. stampedetrial.org
  9. Decipher genomic classifier in NCCN guidelines. decipherbio.com
  10. Philadelphia Consensus on germline testing in prostate cancer. pubmed.gov
  11. NCI: Prostate Cancer Treatment. cancer.gov
  12. American Cancer Society: Prostate Cancer. cancer.org
  13. Prostate Cancer Foundation patient resources. pcf.org
  14. National Society of Genetic Counselors (find a counselor). nsgc.org
  15. ClinicalTrials.gov. clinicaltrials.gov

About this guide. Always work through your own situation with your care team. What the numbers and choices in this guide mean for you depends on your age, your risk group, and what matters to you, so use it as a starting point for that conversation.

Playing audio...